BACKGROUND Because of the shortage of grafts, many attempts have been made to treat calculi in donor kidneys and have achieved successful management. This case report is the first to present removal of stones from bilateral kidneys from a single donor through flexible ureteroscopy before transplantation. CASE REPORT The present case report shows the clinical management of bilateral donor kidneys with calculi, which were taken from a 33-year-old man through donation after cardiac death (DCD). Computed tomography showed 2 stones in the right donor kidney and 1 in the left donor kidney. Two stones were removed ex vivo using a flexible ureteroscope before transplantation, and the third one turned out to be a renal papillae calcification, which was left in place without surgical treatment. The bilateral donor kidneys were transplanted to 2 recipients. CONCLUSIONS There is a possibility of increasing the kidney pool by using donor kidneys containing calculi, which should be removed before transplantation.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5345978PMC
http://dx.doi.org/10.12659/ajcr.902875DOI Listing

Publication Analysis

Top Keywords

donor kidneys
20
case report
16
removal stones
8
donor
8
stones donor
8
flexible ureteroscopy
8
transplantation case
8
bilateral donor
8
kidneys calculi
8
donor kidney
8

Similar Publications

Organ shortage remains a significant challenge in transplantology, prompting efforts to maximize the use of available organs and expand the donor pool, including through extended criteria donors (ECDs). However, ECD kidney recipients often face poorer outcomes, including a higher incidence of delayed graft function (DGF), which is linked to worse graft performance, reduced long-term survival, and an increased need for interventions like dialysis. This underscores the urgent need for strategies to improve early DGF risk assessment and optimize post-transplant management for high-risk patients.

View Article and Find Full Text PDF

Given the significant impact of delayed graft function (DGF) on transplant outcomes, the aim of this study was to develop and validate machine learning (ML) models capable of predicting the risk of DGF in deceased-donor kidney transplantation (DDKT). This retrospective cohort study was conducted using clinical and histopathological data collected between 2018 and 2022 at Ramathibodi Hospital from DDKT donors, recipients, and post-implantation time-zero kidney biopsy samples to develop predictive models. The performance of three ML models (neural network, random forest, and extreme gradient boosting [XGBoost]) and traditional logistic regression on an independent test data set was evaluated using the area under the receiver operating characteristic curve (AUROC) and Brier score calibration.

View Article and Find Full Text PDF

Chronic kidney disease (CKD) is a prevalent disease affecting almost 10% of the world's population, with many cases progressing to end-stage kidney disease (ESKD). Kidney transplantation (KT) is the gold-standard treatment for ESKD. Due to growing KT waitlists, the deceased kidney donor (DKDs) criteria have expanded to increase the number of available kidney grafts.

View Article and Find Full Text PDF

Donor-derived cell-free DNA in chronic lung allograft dysfunction phenotypes: a pilot study.

Front Transplant

December 2024

Laboratory of Respiratory Diseases and Thoracic Surgery (BREATHE), Department of CHROMETA, KU Leuven, Leuven, Belgium.

Long-term survival after lung transplantation is limited due to chronic lung allograft dysfunction (CLAD), which encompasses two main phenotypes: bronchiolitis obliterans syndrome (BOS) and restrictive allograft syndrome (RAS). Donor-derived cell-free DNA (dd-cfDNA) is a biomarker for (sub)clinical allograft injury and could be a tool for monitoring of lung allograft health across the (pre)clinical spectrum of CLAD. In this proof-of-concept study, we therefore assessed post-transplant plasma dd-cfDNA levels in 20 CLAD patients (11 BOS and 9 RAS) at three consecutive time points free from concurrent infection or acute rejection, during stable condition, preclinical CLAD, and established CLAD ( = 3 × 20 samples).

View Article and Find Full Text PDF

The American Transplant Congress (ATC) 2024, held in Philadelphia, serves as a vital platform for unveiling new research and clinical experience in organ machine perfusion-a key area in organ transplantation. This year's congress gathered 4652 participants from 49 countries, including top experts, to spotlight innovations in machine perfusion across various organ types, such as the liver, kidney, heart, and lung. A total of 87 abstracts on organ machine perfusion were presented.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!